Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2016 May 17;25(7):1037–1042. doi: 10.1158/1055-9965.EPI-15-1221

Figure 4. Study B: Presence, sensitivity and specificity of CAMLs in patients with positive mammograms/CBEs compared to standard pathological assessment.

Figure 4

(A) CAMLs were found in all patients with non-invasive disease/Stage 0, in 88% of patients with invasive disease, and 26% of patients with benign conditions. (B) CAMLs were found in a range of 0–8 cells per 7.5 mL sample. (C) ROC curves comparing invasive breast cancer (n=17) to benign conditions (n=19) showed an AUC=0.78. Sensitivity: 88% (CI95% 64–99%) Specificity: 74% (CI95% 49–91%) PPV: 75% (CI95% 51–91%) NPV: 88% (CI95% 62–99%).